Tohidinezhad Fariba, Pennetta Francesca, van Loon Judith, Dekker Andre, de Ruysscher Dirk, Traverso Alberto
Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, Netherlands.
Clin Transl Radiat Oncol. 2022 Feb 22;33:134-144. doi: 10.1016/j.ctro.2022.02.007. eCollection 2022 Mar.
To maximize the likelihood of positive outcome in non-small-cell lung cancer (NSCLC) survivors, potential benefits of treatment modalities have to be weighed against the possibilities of damage to normal tissues, such as the heart. High-quality data-driven evidence regarding appropriate risk stratification strategies is still scarce. The aim of this review is to summarize and appraise available prediction models for treatment-induced cardiac events in patients with NSCLC.
A systematic search of MEDLINE was performed using a Boolean combination of appropriate truncation and indexing terms related to "NSCLC", "prediction models", "cardiac toxicity", and "treatment modalities". The following exclusion criteria were applied: sample-size of less than 100, no significant predictors in multivariate analysis, lack of model specifications, and case-mix studies. The generic inverse variance method was used to pool the summary effect estimate for each predictor. The quality of the papers was assessed using the Prediction model Risk Of Bias Assessment Tool.
Of the 3,056 papers retrieved, 28 prediction models were identified, including seven for (chemo-)radiotherapy, one for immunotherapy, and 20 for surgical resection. Forty-one distinct predictors were entered in the prediction models. The pooled effect estimate of the mean heart dose (HR = 1.06, 95%CI:1.04-1.08) and history of cardiovascular diseases (HR = 3.1, 95%CI:1.8-5.36) were shown to significantly increase the risk of developing late cardiac toxicity after (chemo-)radiotherapy. Summary estimates of age (OR = 1.17, 95%CI:1.06-1.29), male gender (OR = 1.61, 95%CI:1.4-1.85), and advanced stage (OR = 1.34, 95%CI:1.06-1.69) were significantly associated with higher risk of acute cardiac events after surgery. Risk of bias varied across studies, but analysis was the most concerning domain where none of the studies were judged to be low risk.
This review highlights the need for a robust prediction model which can inform patients and clinicians about expected treatment-induced heart damage. Identified clues suggest incorporation of detailed cardiac metrics (substructures' volumes and doses).
为了使非小细胞肺癌(NSCLC)幸存者获得积极结果的可能性最大化,必须权衡治疗方式的潜在益处与对正常组织(如心脏)造成损害的可能性。关于适当风险分层策略的高质量数据驱动证据仍然匮乏。本综述的目的是总结和评估NSCLC患者治疗引起的心脏事件的现有预测模型。
使用与“NSCLC”、“预测模型”、“心脏毒性”和“治疗方式”相关的适当截断词和索引词的布尔组合对MEDLINE进行系统检索。应用以下排除标准:样本量小于100、多变量分析中无显著预测因素、缺乏模型规范以及病例组合研究。使用通用逆方差法汇总每个预测因素的汇总效应估计值。使用预测模型偏倚风险评估工具评估论文质量。
在检索到的3056篇论文中,识别出28个预测模型,包括7个用于(化疗)放疗的模型、1个用于免疫治疗的模型和20个用于手术切除的模型。预测模型中纳入了41个不同的预测因素。平均心脏剂量(HR = 1.06,95%CI:1.04 - 1.08)和心血管疾病史(HR = 3.1,95%CI:1.8 - 5.36)的汇总效应估计值显示,在(化疗)放疗后显著增加发生晚期心脏毒性的风险。年龄(OR = 1.17,95%CI:1.06 - 1.29)、男性(OR = 1.61,95%CI:1.4 - 1.85)和晚期(OR = 1.34,95%CI:1.06 - 1.69)的汇总估计值与手术后急性心脏事件的较高风险显著相关。各研究的偏倚风险各不相同,但分析是最令人担忧的领域,没有一项研究被判定为低风险。
本综述强调需要一个强大的预测模型,该模型可以让患者和临床医生了解预期的治疗引起的心脏损伤。已确定的线索表明应纳入详细的心脏指标(子结构体积和剂量)。